The acquisition is expected to close during the second quarter of fiscal 2021, subject to customary closing conditions, the statement said.
Consideration for the acquisition was not disclosed by Infosys, which has annual revenues of 10 billion U.S. dollar and clients across 46 countries and regions.
Kaleidoscope designs microsurgical instruments, devices used in minimally invasive surgery, drug delivery devices for ophthalmic therapies and user-centric wearables and also offers usability testing in support of regulatory submissions, including the delivery mechanism for aortic stents.
Latest comments